Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nuwellis ( (NUWE) ) just unveiled an update.
On October 7, 2025, Robert B. Scott announced his resignation as Chief Financial Officer of Nuwellis, Inc., effective around October 24, 2025. His departure is not due to any disagreements with the company. The company plans to initiate a search for a new CFO. On October 8, 2025, the Board appointed John L. Erb, the current President and CEO, as interim CFO starting on the separation date. Mr. Erb has extensive experience in the medical device industry and has held various leadership roles within Nuwellis and other companies. His appointment as interim CFO is not accompanied by any additional compensation or changes to his current plans.
The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’ overall stock score is primarily impacted by its financial challenges, including ongoing losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. While recent corporate events and strategic initiatives offer some promise, the immediate financial outlook remains concerning.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Nuwellis, Inc. is a company involved in the medical device industry, focusing on the development, manufacturing, and distribution of devices for treating congestive heart failure and other heart-related conditions.
Average Trading Volume: 924,849
Technical Sentiment Signal: Sell
Current Market Cap: $3.19M
Find detailed analytics on NUWE stock on TipRanks’ Stock Analysis page.